Functional recovery is increasingly recognized as a priority in the treatment of major depressive disorder (MDD), by both clinicians and patients. However, symptom improvement remains the focus of traditional clinical trials for MDD and of the regulatory approval process for new medications and other interventions. Many studies have shown that functional outcomes do not always correspond to symptom-based outcomes.
Methods
Representatives from clinical practice, professional societies, academia, industry, and government were invited by the Canadian Network for Mood and Anxiety Treatments to develop recommendations for the conceptualization and measurement of functional outcomes in clinical trials of MDD.
Results
Definitions and conceptual frameworks to guide assessment of functioning are described, as well as research methodology applicable to the broad spectrum of treatments for MDD. Examples are given for validated instruments, including patient-reported outcome measures. Strategies for knowledge translation and dissemination are suggested and consensus recommendations summarized.
Conclusions
As the societal burden and financial costs of MDD continue to escalate, so does the need for evidence-based and cost-effective interventions that demonstrate improvement in functioning. Routine assessment of functional outcomes will benefit not only individuals with MDD but also diverse stakeholders concerned about the efficacy and cost-effectiveness of interventions.
Get full access to this article
View all access options for this article.
References
1.
World Health Organization. The global burden of disease: 2004 update. Geneva, Switzerland: Press WHO, 2008.
2.
DrussBG, RosenheckRA, SledgeWH.Health and disability costs of depressive illness in a major U.S. corporation. Am J Psychiatry. 2000;157:1274–1278.
3.
WellsKB, StewartA, HaysRD, . The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989;262:914–919.
4.
MoussaviS, ChatterjiS, VerdesE, . Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370:851–858.
5.
AdlerDA, McLaughlinTJ, RogersWH, . Job performance deficits due to depression. Am J Psychiatry. 2006;163:1569–1576.
6.
WeissmanMM.Social functioning and the treatment of depression. J Clin Psychiatry. 2000;61:(suppl 1)33–38.
7.
MooreDJ, MoseleyS, AtkinsonJH.The influence of depression on cognition and daily functioning. In: MarcotteTD, GrantI, eds. Neuropsychology of everyday functioning. New York, NY: Guilford Press; 2010:419–440.
8.
CoonsSJ, RaoS, KeiningerDL, . A comparative review of generic quality-of-life instruments. Pharmacoeconomics. 2000;17:13–35.
9.
ZimmermanM, McGlincheyJB, PosternakMA, . How should remission from depression be defined? The depressed patient's perspective. Am J Psychiatry. 2006;163:148–150.
10.
GreerTL, KurianBT, TrivediMH.Defining and measuring functional recovery from depression. CNS Drugs. 2010;24:267–284.
11.
LamRW, FilteauMJ, MilevR.Clinical effectiveness: the importance of psychosocial functioning outcomes. J Affect Disord. 2011;132:(suppl 1)S9–S13.
12.
LangliebAM, Guico-PabiaCJ.Beyond symptomatic improvement: assessing real-world outcomes in patients with major depressive disorder. Prim Care Companion J Clin Psychiatry. 2010;12. doi: 10.4088/PCC.09r00826blu.
13.
BechP.Social functioning: should it become an endpoint in trials of antidepressants? CNS Drugs. 2005;19:313–324.
14.
KennedyN, FoyK, SheraziR, . Long-term social functioning after depression treated by psychiatrists: a review. Bipolar Disord. 2007;9:25–37.
15.
BeckA, CrainAL, SolbergLI, . Severity of depression and magnitude of productivity loss. Ann Fam Med. 2011;9:305–311.
16.
JuddLL, SchettlerPJ, AkiskalHS.The prevalence, clinical relevance, and public health significance of subthreshold depressions. Psychiatr Clin North Am. 2002;25:685–698.
17.
AscheC V, JoishVN, CamachoF, . The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder. Curr Med Res Opin. 2010;26:1843–1853.
18.
FavaM.Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry. 2004; 65(suppl 16):27–32.
19.
WisniewskiSR, RushAJ, BryanC, . Comparison of quality of life measures in a depressed population. J Nerv Ment Dis. 2007;195:219–225.
20.
FrankE, PrienRF, JarrettRB, . Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48:851–855.
21.
McKnightPE, KashdanTB.The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev. 2009;29:243–259.
22.
KennedySH, LamRW, ParikhS V, . Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. J Affect Disord. 2009; 117:S1–S64.
23.
BerardiD, Berti CeroniG, LeggieriG, . Mental, physical and functional status in primary care attenders. Int J Psychiatry Med. 1999;29:133–148.
24.
MondlochMV, ColeDC, FrankJW.Does how you do depend on how you think you'll do? A systematic review of the evidence for a relation between patients’ recovery expectations and health outcomes. CMAJ. 2001;165:174–179.
25.
BaumCM, KatzN.Occupational therapy approach to assessing the relationship between cognition and function. In: MarcotteTD, GrantI, eds. Neuropsychology of everyday functioning. New York, NY: Guilford Press; 2010:62–90.
26.
FaerdenA, NesvågR, MarderSR.Definitions of the term ‘recovered’ in schizophrenia and other disorders. Psychopathology. 2008;41:271–278.
27.
MoherD, SchulzKF, AltmanDG.The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol. 2001;1:2.
28.
HamiltonM.A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
29.
MontgomerySA, AsbergM.A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.
30.
BartonKN.Health Canada Regulatory Considerations for Functional Outcomes in Depression. Plenary session at the CANMAT Consensus Statement Conference on Functional Outcomes in Depression Clinical Trials; February 10, 2012; Ottawa ON, Canada.
GotlibIH, JoormannJ.Cognition and depression: current status and future directions. Annu Rev Clin Psychol. 2010;6:285–312.
34.
CarswellA, McCollMA, BaptisteS, . The Canadian Occupational Performance Measure: a research and clinical literature review. Can J Occup Ther. 2004;71:210–222.
35.
LeonAC, OlfsonM, PorteraL, . Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med. 1997;27:93–105.
36.
EndicottJ, SpitzerRL, FleissJL, . The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33:766–771.
37.
BoscM, DubiniA, PolinV.Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur Neuropsychopharmacol. 1997;7:(suppl 1)S57–S70; discussion S71-S71.
38.
WeissmanMM, MHS Staff. Social Adjustment Scale– Self Report (SAS-SR): User's Manual.North Tonwanda, NY/Toronto ON, Canada: Multi-Health Systems Inc; 1999.
39.
Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association; 2000.
40.
World Health Organization. WHO psychiatric disability assessment schedule (WHO/DAS): with a guide to its use. Geneva, Switzerland: WHO Press; 1988.
41.
KesslerRC, BarberC, BeckA, . The World Health Organization Health and Work Performance Questionnaire (HPQ). J Occup Environ Med. 2003;45:156–174.
42.
EndicottJ, NeeJ.Endicott Work Productivity Scale (EWPS): a new measure to assess treatment effects. Psychopharmacol Bull. 1997;33:13–16.
43.
LamRW, MichalakEE, YathamLN.A new clinical rating scale for work absence and productivity: validation in patients with major depressive disorder. BMC Psychiatry. 2009;9:78.
44.
KoopmanC, PelletierKR, MurrayJF,. Stanford presenteeism scale: health status and employee productivity. J Occup Environ Med. 2002;44:14–20.
45.
LernerD, AmickBC3rd, RogersWH, . The work limitations questionnaire. Med Care. 2001;39:72–85.
46.
ReillyMC, ZbrozekAS, DukesEM.The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4:353–365.
47.
MundtJC, MarksIM, ShearMK, . The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002;180:461–464.
48.
MooreDJ, PalmerBW, PattersonTL, . A review of performance-based measures of functional living skills. J Psychiatr Res. 2007;41:97–118.
49.
FrostMH, ReeveBB, LiepaAM, . What is sufficient evidence for the reliability and validity of patient-reported outcome measures?Value in Health.2007;10:(suppl 2)S94–S105.
50.
Department U.S. of Health and Human Services – Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Published December 2009. Accessed February 20, 2015.
51.
ScogginsJF, PatrickDL.The use of patient-reported outcomes instruments in registered clinical trials: evidence from ClinicalTrials. gov. Contemp Clin Trials. 2009;30:289–292.
52.
CarterJD, FramptonCM, MulderRT, . The relationship of demographic, clinical, cognitive and personality variables to the discrepancy between self and clinician rated depression. J Affect Disord. 2010;124:202–206.
53.
CopayAG, SubachBR, GlassmanSD, . Understanding the minimum clinically important difference: a review of concepts and methods. Spine J.2007;7:541–546.
54.
CrosbyRD, KolotkinRL, WilliamsGR.Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56:395–407.
55.
RevickiDA, CellaD, HaysRD, . Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes. 2006;4:70.
56.
AbmaFI, van der KlinkJJ, TerweeCB, . Evaluation of the measurement properties of self-reported health-related work-functioning instruments among workers with common mental disorders. Scand J Work Environ Health. 2012;38:5–18.
57.
BackenstrassM, FrankA, JoestK, . A comparative study of nonspecific depressive symptoms and minor depression regarding functional impairment and associated characteristics in primary care. Compr Psychiatry. 2006;47:35–41.
58.
TrivediMH.Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. J Clin Psychiatry. 2009;70:(suppl 6)26–31.
59.
TrivediMH, DalyEJ.Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend. 2007;88:(suppl 2)S61–S71.
60.
DavidsonL, DrakeRE, SchmutteT, . Oil and water or oil and vinegar? Evidence-based medicine meets recovery. Community Ment Health J. 2009; 45:323–332.
61.
ScottSD, AlbrechtL, O'LearyK, . A protocol for a systematic review of knowledge translation strategies in the allied health professions. Implement Sci. 2011;6:58.
62.
Canadian Institutes of Health Research. Innovation in Action: The CIHR Knowledge Translation Strategy 2004-2009. Ottawa ON, Canada: Government of Canada; 2004.
63.
World Health Organization. Bridging the “know-do” gap: meeting on knowledge translation in global health. Geneva, Switzerland: WHO Press; 2006.
64.
Diagnostic and statistical manual of mental disorders, 5th edition.Washington, DC: American Psychiatric Association; 2013.
65.
BakishD.New standard of depression treatment: remission and full recovery. J Clin Psychiatry. 2001; 62(suppl 26):5–9.
66.
Keller PastMB., present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA. 2003;289:3152–3160.
67.
KelseyJE.Clinician perspective on achieving and maintaining remission in depression. J Clin Psychiatry. 2001;62:(suppl 26)16–21.
